NEA Management Company LLC Buys Shares of 6,467,802 Regulus Therapeutics Inc. (NASDAQ:RGLS)

NEA Management Company LLC purchased a new position in shares of Regulus Therapeutics Inc. (NASDAQ:RGLS - Free Report) during the third quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 6,467,802 shares of the biopharmaceutical company's stock, valued at approximately $10,154,000. Regulus Therapeutics accounts for 0.6% of NEA Management Company LLC's holdings, making the stock its 27th biggest position. NEA Management Company LLC owned about 9.87% of Regulus Therapeutics at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of RGLS. Creative Planning purchased a new position in shares of Regulus Therapeutics in the third quarter worth about $26,000. SG Americas Securities LLC purchased a new stake in Regulus Therapeutics during the 3rd quarter valued at $33,000. Rhumbline Advisers purchased a new stake in Regulus Therapeutics in the 2nd quarter worth $136,000. Tyche Wealth Partners LLC grew its position in shares of Regulus Therapeutics by 920.6% during the third quarter. Tyche Wealth Partners LLC now owns 106,089 shares of the biopharmaceutical company's stock valued at $167,000 after purchasing an additional 95,694 shares in the last quarter. Finally, The Manufacturers Life Insurance Company bought a new position in shares of Regulus Therapeutics in the 3rd quarter valued at about $204,000. 92.38% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts have issued reports on RGLS shares. StockNews.com raised shares of Regulus Therapeutics to a "sell" rating in a report on Tuesday, September 17th. Oppenheimer reiterated an "outperform" rating and set a $7.00 target price on shares of Regulus Therapeutics in a report on Wednesday, August 14th. Finally, HC Wainwright reissued a "buy" rating and set a $10.00 price objective on shares of Regulus Therapeutics in a research report on Monday, November 11th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, Regulus Therapeutics has a consensus rating of "Moderate Buy" and an average target price of $10.80.

Regulus Therapeutics Stock Down 1.8 %

RGLS traded down $0.03 during trading on Friday, reaching $1.61. 158,165 shares of the company's stock were exchanged, compared to its average volume of 335,858. The company has a market capitalization of $105.46 million, a P/E ratio of -1.50 and a beta of 1.63. Regulus Therapeutics Inc. has a fifty-two week low of $1.08 and a fifty-two week high of $3.79. The business has a 50 day moving average price of $1.52 and a 200 day moving average price of $1.74.

Regulus Therapeutics (NASDAQ:RGLS - Get Free Report) last released its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.03). As a group, research analysts forecast that Regulus Therapeutics Inc. will post -0.88 EPS for the current year.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.